x
- Home
- About Diabetes
- Services
- Diabetes Mellitus Modeling Solutions
- R&D Services for Diabetes Mellitus and Diabetic Complications
- By Drug Development Process
- About Us
- Careers
- Contact Us
Cat. No.: DAA-001308
| Product Information | |
|---|---|
| Product Name | Rat Serpin A12 Antibody Pair - BSA and Azide free |
| Species | Rat |
| Description | The Antibody Pair can be used to quantify Rat Serpin A12. BSA and Azide free antibody pairs include unconjugated capture and detector antibodies suitable for sandwich ELISAs. The antibodies are provided at an approximate concentration of 1 mg/ml as measured by the protein A280 method. The recommended antibody orientation is based on internal optimization for ELISA-based assays. Antibody orientation is assay dependent and needs to be optimized for each assay type. Both capture and detector antibodies are rabbit monoclonal antibodies delivering consistent, specific, and sensitive results. |
| Detection Range | 23.438 pg/mL - 1500 pg/mL |
| Precision | Intra-assay precision CV ≤ 10.0%; Inter-assay precision CV ≤ 10.0% |
| Target Information | |
|---|---|
| Target Name | SERPINA12 |
| UniProt No. | Q8IW75 |
| Gene ID | 145264 |
| Target Description | May modulates insulin action conceivably only in the presence of its yet undefined target proteases in white adipose tissues. |
| Alternative Names | ENSG00000165953; OL 64; OL-64; OL64; Serine (or cysteine) proteinase inhibitor clade A (alpha 1 antiproteinase antitrypsin) member 12; Serpin A12; Serpin A12 precursor; Serpin peptidase inhibitor clade A (alpha 1 antiproteinase antitrypsin) member 12; Serpina12; SPA12_HUMAN; Vaspin; Visceral adipose specific serpin; Visceral adipose tissue derived serine protease inhibitor; Visceral adipose tissue-derived serine protease inhibitor; Visceral adipose-specific serpin |
| Shipping & Storage | |
|---|---|
| Sipping | Shipping on dry ice. |
| Storage | Store at +4°C. Please refer to protocols. |
Ace Therapeutics has a team of experts in the field of endocrine and metabolic research, aiming to provide innovative preclinical contract research solutions to cope with diabetes and its complications. We provide customized solutions and technical support, enabling the transformation of promising concepts into innovative treatments, thus accelerating the drug development process of diabetes.
